Australia's CSL strikes kidney, liver disease drug deal worth up to $1.6 billion
04/10/2026 22:37
Australia's CSL strikes kidney, liver disease drug deal worth up to $1.6 billion Oct 5 (Reuters) - Australia's CSL CSL.AX said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development funding.
(Reporting by Rajasik Mukherjee in Bengaluru; Editing by Nia Williams)
Recent news on CSL
See all newsCiti says CSL's CEO pick brings key strengths
Australia's CSL names GSK executive Waterhouse as next CEO (updated)
Brief: CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director
Australia's CSL appoints Deborah Waterhouse as CEO
Early US flu season, current strain may signal risk for younger people; doctors urge shots